BRIEF-Aralez Pharmaceuticals' drug BLEXTEN receives Health Canada approval
April 25 (Reuters) - Aralez Pharmaceuticals Inc
* Aralez pharmaceuticals says Health Canada approved BLEXTEN for treatment of symptoms of seasonal allergic rhinitis, chronic spontaneous urticaria
* BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc., a subsidiary of company Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.